SCHEMBL8077995

SCHEMBL8077995

C=C/C=N\C=N/C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12092410 0.73
SCHEMBL2241560 0.72
SCHEMBL882256 0.72
SCHEMBL2241562 0.72
SCHEMBL9069580 0.71
SCHEMBL13893602 0.69
SCHEMBL14748636 0.69
SCHEMBL12948132 0.69
SCHEMBL18896666 0.69
SCHEMBL18608946 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3735411-B1 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE AC IMMUNE SA (CH) 2024-07-10 EP disclosed
EP-4269413-A1 A METHOD FOR SYNTHESIZING A TWO-DIMENSIONAL MATERIAL CONSISTING OF CONJUGATED AROMATIC STRUCTURES BY TRIMERIZATION Freie Universität Berlin (DE) 2023-11-01 EP disclosed
WO-2023001177-A1 LPA1 SMALL MOLECULE ANTAGONIST 上海拓界生物医药科技有限公司 2023-01-26 WO disclosed
US-20220402950-A1 SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2022-12-22 US disclosed
US-11236111-B2 Hepatitis B antiviral agents ENANTA PHARMACEUTICALS, INC. (US) 2022-02-01 US disclosed
US-20210053973-A1 IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2021-02-25 US disclosed
US-20200377519-A1 HEPATITIS B ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2020-12-03 US disclosed
WO-2019143678-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-07-25 WO disclosed
US-10301306-B2 Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2019-05-28 US disclosed
WO-2019049965-A1 COMPOUND HAVING PYRIMIDINE RING STRUCTURE AND ORGANIC ELECTROLUMINESCENT ELEMENT 保土谷化学工業株式会社 2019-03-14 WO disclosed
US-9598423-B2 Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-03-21 US disclosed
EP-2935272-B1 PYRAZOLE SUBSTITUTED IMIDAZOPYRAZINES AS CASEIN KINASE 1 D/E INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-02-22 EP disclosed
US-9556179-B2 Substituted imidazoles as casein kinase 1 D/E inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-01-31 US disclosed
EP-2910555-A1 Organic electroluminescent materials and devices Universal Display Corporation (US) 2015-08-26 EP disclosed
EP-2638022-B1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 BRISTOL MYERS SQUIBB CO (US) 2014-12-24 EP disclosed
WO-2014100533-A1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-06-26 WO disclosed
US-8519384-B2 Phosphorescent materials UNIVERSAL DISPLAY CORPORATION (US) 2013-08-27 US disclosed
US-20130168660-A1 ORGANOSELENIUM MATERIALS AND THEIR USES IN ORGANIC LIGHT EMITTING DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2013-07-04 US disclosed
WO-2012068366-A2 BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS YALE UNIVERSITY (US) 2012-05-24 WO disclosed
WO-2008137816-A2 TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS WYETH (US) 2008-11-13 WO disclosed